公开(公告)号：US20190022641A1

公开(公告)日：2019-01-24

申请号：US15752228

申请日：2016-08-12

Applicant: Dyax Corp.

Inventor： Daniel J. Sexton ,  Ryan Faucette

IPC: B01L3/00 ,  G01N33/573 ,  C07K16/40 ,  G01N33/96 ,  G01N33/564

Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.

公开(公告)号：US20150362493A1

公开(公告)日：2015-12-17

申请号：US14761690

申请日：2014-01-17

Applicant: DYAX CORP.

Inventor： Daniel J. Sexton ,  Ryan Faucette ,  Jon A. Kenniston ,  Gregory P. Conley ,  Andrew Nixon ,  Christopher TenHoor ,  Burt Adelman ,  Yung Chyung

IPC: G01N33/573 ,  C07K7/06 ,  C07K16/40

CPC classification number: G01N33/5735 ,  C07K7/06 ,  C07K16/36 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/76 ,  G01N2333/745 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/52 ,  G01N2800/70

Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.

Abstract translation: 本公开提供了评估受试者的方法，例如，基于pKal介导的或缓激肽介导的病症的风险或患有pKal介导的或缓激肽介导的病症的受试者，基于样品中完整和/或切割的激肽原的值（例如，百分比） 学科。 提供的方法允许对血浆激肽释放酶介导的血管性水肿（KMA）或由pKal介导的其它疾病的患者进行分析，其可用于评估和治疗。 这样的方法可以涉及使用优先结合切割的激肽原或完整激肽原的检测剂。